Влияние Септолете® Тотал на возбудителя COVID-19

1. Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis. 2005;5(11):718‑25. DOI:10.1016/S1473-3099(05)70270-X
2. Su S, Wong G, Shi W, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016;24(6):490-502. DOI:10.1016/j.tim.2016.03.003
3. De Wit E, van Doremalen N, Falzarano D, Munster VJ. 2016 SARS and MERS: Recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-34. DOI:10.1038/nrmicro.2016.81
4. Worldometer. Coronavirus Cases. 2021. Available at: https://www.worldometers.info/coronavirus/?zarsrc=130. Accessed: 22.04.2021
5. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID‐19 patients in northeast Chongqing. J Med Virol. 2020;92(7):797-806. DOI:10.1002/jmv.25783
6. Hassan SA, Sheikh FN, Jamal S, et al. Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment. Cureus. 2020;12(3):e7355. DOI:10.7759/cureus.7355
7. Бевова М.Р., Нетесов С.В., Аульченко Ю.С. Новая коронавирусная инфекция COVID-19. Молекулярная генетика, микробиология и вирусология. 2020;38(2):51-8. DOI:10.17116/molgen20203802151
8. Хайтович А.Б. Коронавирусы (таксономия, структура вируса). Крымский журнал экспериментальной и клинической медицины. 2020;10(3):69-81.
DOI:10.37279/2224-6444-2020-10-3-69-81
9. Супотницкий М.В. Новый коронавирус SARS-CoV-2 в аспекте глобальной эпидемиологии коронавирусных инфекций. Вестник войск РХБ защиты. 2020;4(1):32-65. DOI:10.35825/2587-5728-2020-4-1-32-65
10. Yoon JG, Yoon J, Song JY, et al. Clinical significance of a high SARS-CoV-2 viral load in the saliva. J Korean Med Sci. 2020;35(20):e195. DOI:10.3346/jkms.2020.35.e195
11. To KK, Tsang OT, Yip CC, et al. Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin Infect Dis. 2020;71(15):841-3. DOI:10.1093/cid/ciaa149
12. Baghizadeh Fini M. Oral saliva and COVID-19. Oral Oncol. 2020;108:104821. DOI:10.1016/j.oraloncology.2020.104821
13. Herrera D, Serrano J, Roldán S, Sanz M. Is the oral cavity relevant in SARS-CoV-2 pandemic? Clin Oral Investig. 2020;24(8):2925-30. DOI:10.1007/s00784-020-03413-2
14. Mateos-Moreno MV, Mira A, Ausina-Márquez V, Ferrer MD. Oral antiseptics against coronavirus: in-vitro and clinical evidence. J Hosp Infect. 2021;113:30-43. DOI:10.1016/j.jhin.2021.04.004
15. Xu R, Cui B, Duan X, et al. Saliva: potential diagnostic value and transmission of 2019-nCoV. Int J Oral Sci. 2020;12(1):11. DOI:10.1038/s41368-020-0080-z
16. Hormati A, Ghadir MR, Foroghi Ghomi SY, et al. Can increasing the number of close contact lead to more mortality in COVID-19 infected patients? Iran J Public Health. 2020;49(Suppl. 1):117-8. DOI:10.18502/ijph.v49is1.3680
17. Свистушкин В.М., Никифорова Г.Н., Шевчик Е.А., Топоркова Л.А. Эффективность топических препаратов в лечении больных острыми воспалительными заболеваниями глотки. Вестник оториноларингологии. 2019;84(6):112-7. DOI:10.17116/otorino201984061112
18. Morokutti-Kurz M, Graf C, Prieschl-Grassauer E. Amylmetacresol/2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat. Int J Gen Med. 2017;10:53-60. DOI:10.2147/IJGM.S120665
19. Paley O. Cetylpyridinium chloride. Synlett. 2014;25:599-600. DOI:10.1055/s-0033-1340488
20. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999;12(1):147-79. DOI:10.1128/CMR.12.1.147
21. Quisno R, Foter MJ. Cetyl pyridinium chloride: I. Germicidal properties. J Bacteriol. 1946;52:111-7. DOI:10.1128/JB.52.1.111-117.1946
22. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol. 2005;99(4):703-15. DOI:10.1111/j.1365-2672.2005.02664.x
23. Carmona-Ribeiro AM, de Melo Carrasco LD. Cationic antimicrobial polymers and their assemblies. Int J Mol Sci. 2013;14(5):9906-46. DOI:10.3390/ijms14059906
24. Pitten FA, Kramer A. Efficacy of cetylpyridinium chloride used as oropharyngeal antiseptic. Arzneimittelforschung. 2001;51(7):588-95. DOI:10.1055/s-0031-1300084
25. Maillard JY. Bacterial target sites for biocide action. J Appl Microbiol. 2002;92 Suppl.:16S-27S.
26. Bereswill S, Vey T, Kist M. Susceptibility in vitro of Helicobacter pylori to cetylpyridinium chloride. FEMS Immunol Med Microbiol. 1999;24(2):189-92.
DOI:10.1111/j.1574-695X.1999.tb01281.x
27. Latimer J, Munday JL, Buzza KM, et al. Antibacterial and anti-biofilm activity of mouthrinses containing cetylpyridinium chloride and sodium fluoride. BMC Microbiol. 2015;15:169. DOI:10.1186/s12866-015-0501-x
28. Giuliana G, Pizzo G, Milici ME, Giangreco R. In vitro activities of antimicrobial agents against Candida species. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;87(1):44-9. DOI:10.1016/s1079-2104(99)70293-3
29. Mao X, Auer DL, Buchalla W, et al. Cetylpyridinium Chloride: Mechanism of Action, Antimicrobial Efficacy in Biofilms, and Potential Risks of Resistance. Antimicrob Agents Chemother. 2020;64(8):e00576-20. DOI:10.1128/AAC.00576-20
30. Cieplik F, Kara E, Muehler D, et al. Antimicrobial efficacy of alternative compounds for use in oral care toward biofilms from caries‐associated bacteria in vitro. Microbiologyopen. 2019;8(4):e00695. DOI:10.1002/mbo3.695
31. Smith K, Robertson DP, Lappin DF, Ramage G. Commercial mouthwashes are ineffective against oral MRSA biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(5):624-9. DOI:10.1016/j.oooo.2012.12.014
32. Popkin DL, Zilka S, Dimaano M, et al. Cetylpyridinium chloride (CPC) exhibits potent, rapid activity against influenza viruses in vitro and in vivo. Pathog Immun. 2017;2(2):253-69. DOI:10.20411/pai.v2i2.200
33. Mukherjee PK, Esper F, Buchheit K, et al. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. BMC Infect Dis. 2017;17(1):74. DOI:10.1186/s12879-016-2177-8
34. Eduardo FP, Corrêa L, Heller D, et al. Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial. Heliyon. 2021;7(6):e07346. DOI:10.1016/j.heliyon.2021.e07346
35. Meyers C, Robison R, Milici J, et al. Lowering the transmission and spread of human coronavirus. J Med Virol. 2021:93(3):1605-12. DOI:10.1002/jmv.26514
36. Seneviratne C, Balan P, Kwan KK, Udawatte NS. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore Chaminda. Infection. 2021;49(2):305-11. DOI:10.1007/s15010-020-01563-9
37. Carrouel F, Gonçalves LS, Conte MP, et al. Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2. J Dent Res. 2021;100(2):124-32. DOI:10.1177/0022034520967933
38. Baker N, Williams AJ, Tropsha A, Ekins S. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19. Pharm Res. 2020;37(6):104.
DOI:10.1007/s11095-020-02842-8
39. Steyer A, Marušić M, Kolenc M, Triglav T. A Throat Lozenge with Fixed Combination of Cetylpyridinium Chloride and Benzydamine Hydrochloride Has Direct Virucidal Effect on SARS-CoV-2. COVID. 2021;1(2):435‑46. DOI:10.3390/covid1020037
40. Darnell MER, Subbarao K, Feinstone SM, Taylor DR. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J Virol Methods. 2004;121(1):85-91. DOI:10.1016/j.jviromet.2004.06.006

О.В. Филиппова

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия